Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders by Francis, S. M. et al.
Oxytocin and vasopressin systems in genetic syndromes and 
neurodevelopmental disorders
S.M. Francisa, A. Sagarb, T. Levin-Decaninia, W. Liuc, C.S. Carterd, and S. Jacoba,*
aUniversity of Minnesota, Department of Psychiatry, Minneapolis, MN, USA
bUniversity of California at Irvine, Department of Psychiatry and Human Behavior, USA
cNorthwestern University, Feinberg School of Medicine, Chicago, IL, USA
dUniversity of North Carolina, Department of Psychiatry, Chapel Hill, NC, USA
Abstract
Oxytocin (OT) and arginine vasopressin (AVP) are two small, related neuropeptide hormones 
found in many mammalian species, including humans. Dysregulation of these neuropeptides have 
been associated with changes in behavior, especially social interactions. We review how the OT 
and AVP systems have been investigated in Autism Spectrum Disorder (ASD), Prader–Willi 
Syndrome (PWS), Williams Syndrome (WS) and Fragile X syndrome (FXS). All of these 
neurodevelopmental disorders (NDD) are marked by social deficits. While PWS, WS and FXS 
have identified genetic mutations, ASD stems from multiple genes with complex interactions. 
Animal models of NDD are invaluable for studying the role and relatedness of OT and AVP in the 
developing brain. We present data from a FXS mouse model affecting the fragile X mental 
retardation 1 (Fmr1) gene, resulting in decreased OT and AVP staining cells in some brain 
regions. Reviewing the research about OT and AVP in these NDD suggests that altered OT 
pathways may be downstream from different etiological factors and perturbations in development. 
This has implications for ongoing studies of the therapeutic application of OT in NDD.
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1. Introduction to OT and AVP neuropeptide hormones
Oxytocin (OT) and arginine vasopressin (AVP) are small mammalian neuropeptides nine 
amino acids in length, which differ by only two amino acids. OT is produced primarily in 
hypothalamic nuclei, including the supraoptic (SON) and paraventricular nuclei (PVN). 
AVP is also synthesized in the PVN and SON. In males, additional brain regions including 
the amygdala and the bed nucleus of the stria terminalis (BNST) also produce AVP. OT and 
AVP of hypothalamic origins are transported from the SON and PVN to the mammalian 
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posterior pituitary by neurosecretion where they are released into the blood stream and act as 
hormones on target tissues. In addition, both OT and AVP are capable of moving throughout 
the central nervous system via diffusion in the cerebral spinal fluid (CSF; Neumann and 
Landgraf, 2012). The peptide-producing OT gene (OXT) is homologous with its 
evolutionarily related gene, vasopressin (AVP). The human OXT and AVP genes linked on 
chromosome 20p13 are separated by only 12 kilobases of DNA, and are positioned in 
opposite transcriptional orientations. Both have specific receptors, but their close 
evolutionary relationship permits cross-talk and interacting molecular systems. These 
neuropeptide hormones have receptors in various brain regions and throughout the body, 
including areas that are important for regulating social behavior and reactivity to stressors.
In both, the human and mouse genomes OT and AVP neuropeptide genes are located 
adjacently on the same chromosome. Often the blood levels of both hormones are highly 
correlated (Dai et al., 2012), suggesting a coordinated release. The receptors for both 
neuropeptides are localized in specific areas of the nervous system, especially in the 
brainstem. These brain regions influence social and adaptive behaviors, as well as regulate 
the hypothalamic–pituitary–adrenal axis (HPA) and autonomic nervous systems (Lim et al., 
2005, 2004). Because OT and AVP are closely related and have the ability to act on the 
other’s receptors, it has been proposed that they evolved to interact and sometimes have 
opposing physiological effects. For example, both hormones have been shown to affect the 
control of the autonomic nervous system, with OT having primarily parasympathetic actions 
and AVP serving as a central and peripheral regulatory component of the sympathetic 
nervous system and HPA axis (Kenkel et al., 2012; Sawchenko and Swanson, 1985). 
However, at high levels the neuropeptides can be partial agonists for their homologous 
receptors, which may result in AVP and OT pathways interacting (Chini et al., 1996).
Of particular importance in neurodevelopmental disorders (NDD) is the fact that OT and 
AVP can modulate social and repetitive behavior and other manifestations of anxiety and 
state regulation (Carter, 2007). Animal research has generally associated OT release or 
exposure with positive sociality, reduced anxiety, and lower levels of reactivity to stressors 
(Carter, 1998; Neumann and Landgraf, 2012). AVP influences anxiety, the regulation of 
HPA and stress responses. In general, central AVP is described as anxiogenic (Landgraf and 
Wigger, 2003). However, there is also evidence in rats that the effects of AVP are brain 
region specific and dose-dependent. For example, AVP may be anxiolytic if given in low 
doses (Appenrodt et al., 1998).
Mouse knockout (KO) studies of the OT receptor (OXTR) or OT regulators have found 
decreased social memory or recognition (Ferguson et al., 2000; Jin et al., 2007; Takayanagi 
et al., 2005). Oxtr KO mice also displayed decreased cognitive flexibility and a resistance to 
change of a learned pattern of behavior that is comparable to restricted/repetitive interests 
(Sala et al., 2011). Both social deficits and behavioral rigidity were ameliorated by OT 
administration (Sala et al., 2011). The finding that OT continues to have effects in Oxtr KO 
mice supports the hypothesis that OT can influence behavior through other receptors, 
especially the AVP receptors (e.g. AVPR1A and/or AVPR1B). Given the influence of these 
neuropeptides on brain regions affecting both social and repetitive behaviors, modulation of 
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OT and AVP pathways are being explored as treatment targets for disorders, including 
Fragile X syndrome (FXS) and Autism Spectrum Disorders (ASD).
This and other research has set the stage for a series of recent studies on the effects of 
exogenous OT treatments in humans (Ebstein et al., 2012; Macdonald and Feifel, 2013). For 
example, intranasal OT (IN-OT) administration in healthy human males increased prosocial 
behaviors and trust, especially as measured by experimental economic games (Baumgartner 
et al., 2008; Kirsch, 2005; Kosfeld et al., 2005). IN-OT may also increase gaze towards the 
eye region of the face (Guastella et al., 2008), and has been associated with improved facial 
memory (Rimmele et al., 2009), enhanced salience of social cues (Shamay-Tsoory et al., 
2009), and improved performance on the reading the mind in the eyes (RMET) task (Domes 
et al., 2007).
As previously reviewed, OT has been found to have anxiolytic effects improving social 
interactions, reducing fear, and improving the ability of healthy volunteers to interpret subtle 
social cues (Macdonald and Macdonald, 2010). In addition, OT dysfunction has been 
associated with neurop-sychiatric disorders such as autism in human studies (Domes et al., 
2007; Ishak et al., 2011; Winslow and Insel, 2004). By 2010 there were over 20 OT 
administration studies, which included ASD, schizophrenia, postpartum depression, 
posttraumatic stress disorder (PTSD), and irritable bowel syndrome (Macdonald and 
Macdonald, 2010). There have been a growing number of studies investigating the ability of 
IN-OT to treat a range of neurobehavioral disorders due to the associations between IN-OT 
and alterations in social decision-making, processing of social stimuli, certain social 
behaviors such as eye contact, and social memory.
2. Autism spectrum disorders
In 1943, Leo Kanner described a male patient with repetitive behaviors—”stereotyped 
movements [and]…repetitions carried out in exactly the same way in which they had been 
performed originally” and difficulties with social communication—”he always seemed to be 
parroting what he had heard said to him at one time or another…Words to him had a 
specifically literal, inflexible meaning. He seemed unable to generalize, to transfer an 
expression to another similar object or situation” (Kanner, 1943). This group of symptoms, 
later extended and described in detail, is currently known as ASD. As described in the 
DSM-5 (American Psychiatric Association, 2013), ASD is characterized by persistent 
deficits in social communication and social interaction across multiple contexts, and the 
diagnosis requires the presence of restricted, repetitive patterns of behaviors, interests, or 
activities. ASD is a heritable (Bailey et al., 1995) and highly heterogeneous disorder, caused 
by familial genetic risks in addition to possible gene-environment interactions during early 
development (Chaste and Leboyer, 2012). Individuals with ASD often suffer with anxiety 
disorders, irritability or aggression, and come to clinical attention due to their difficulties at 
home and school related to their communication deficits and restricted interests. 
Unfortunately there are currently no approved medications to treat the social deficits or 
restricted, repetitive behaviors (RRB) that are the core symptoms of ASD. There is some 
evidence in animal and human studies that OT improves the core symptoms of ASD.
Francis et al. Page 3






















2.1. Intranasal andintravenous OT studies in ASD
Currently medications for ASD concentrate on alleviating certain symptoms, but not the 
core features of ASD. Risperidone and aripiprazole may be used for irritability, whereas 
guanfacine and clonidine are used off label for aggression, and selective serotonin reuptake 
inhibitors (SSRI; i.e. escitalopram, fluoxetine, and sertraline) are used to treat anxiety 
(Jaselskis et al., 1992; McCracken et al., 2002; Owley et al., 2010). Recently, OT has been 
investigated as a target the treatment for ASD core symptoms, social deficits and RRB. 
Defined by DSM-5, restricted, repetitive patterns of behavior include stereotyped or 
repetitive motor movements, insistence on sameness, inflexible adherence to routines, or 
ritualized patterns of verbal or nonverbal behavior. Highly restricted, fixated interests that 
are abnormal in intensity or focus, and hyper- or hyporeactivity to sensory input or unusual 
interest in sensory aspects of the environment are also RRB.
Several studies, using intravenous OT or IN-OT, in patients with ASD have been conducted 
(Table 1). It has been shown that nonapeptides, like AVP, can be measured in CSF after 
intranasal administration (Born et al., 2002). Ease of giving intranasal drugs makes it 
preferred for most ASD studies, although more research needs to be conducted on how IN-
OT reaches the brain and how it regulates receptors and neural pathways with different or 
chronic dosing strategies. Several studies have measured OT responses to single dose 
challenges in ASD (Andari et al., 2010; Guastella et al., 2010), while few have examined 
longer term treatment effects (Anagnostou et al., 2012). With varying administration and 
duration study protocols, studies have often focused on symptom subdomains or defined 
social tasks including: RRB (Hollander et al., 2003), emotion recognition (Dadds et al., in 
press; Guastella et al., 2010), affective speech comprehension (Hollander et al., 2007), and 
facial recognition (Domes et al., 2013).
Single dose studies, or challenges, have been utilized to study the acute and immediate 
effects of OT. An initial study in ASD examined the effects of a four-hour continuous dose 
of intravenous OT (Hollander et al., 2003). After one hour of infusion there was a decrease 
in RRB (repeating and touching). After four hours, 13 patients (86.7%) versus six control 
subjects (40%) had decreases in RRB. This study demonstrated that administration of OT 
led to a decrease in a core ASD symptom, RRB. More recently, a double-blind, randomized, 
placebo controlled study of IN-OT in 16 males with ASD (ages 12–19 years old) showed 
that a single IN-OT dose could improve the ability to recognize emotion, particularly in easy 
queries (Guastella et al., 2010). It is unclear whether emotion recognition performance goes 
back to baseline or pre-OT exposure after a single dose or if there are long-term learning 
effects.
Andari et al. (2010) also performed a single dose IN-OT study in 13 individuals with ASD 
and in age-matched controls to study the effect on social deficits. They researched the 
effects of IN-OT on trust and preference using a social ball tossing game (for greater detail 
of this task please see supplementary section of Andari et al., 2010). This group also 
assessed the visual scanning of faces under the influence of IN-OT. They found that patients 
given IN-OT had a significant preference for the “good player” (the computer player who 
tossed the ball back to the individual) that was similar to the control subjects also 
performing the task. This preference was further supported by the patients’ reporting of 
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trust, towards the “good player” after OT administration. Andari and colleagues also found 
that after IN-OT, patients increased eye gazing time on the socially informative region of the 
face. While single dose studies are valuable, evaluating long term effects of OT are essential 
to determine if OT has a therapeutic potential in ASD (Macdonald and Feifel, 2013).
Recently a five-day OT administration study was conducted during parent–child interaction 
training (Dadds et al., in press). Individuals with high functioning ASD received 12 or 24 IU 
(depending on the weight of the patient) IN placebo or IN-OT. The OT or placebo was 
administered once daily and RRB, emotion recognition, social interaction skills, and general 
behavioral adjustment were assessed. While improvements over time were detected in both 
OT and placebo, there were no differences observed between the two groups. Several 
proposed possible explanations for these null findings were: (1) emotion recognition was 
measured pre-post changes following multiple exposures versus while the patient was under 
the influence; (2) lower-order RRB respond to OT (Hollander et al., 2003), while higher-
order RRB do not (Anagnostou et al., 2012); (3) increased eye gaze frequency is usually 
measured with artificial or computerized faces, while they had “real-life” interactions; (4) 
the OT receptor system disruptions in some patients with ASD may respond differently than 
in other ASD patients; and (5) differences between the studies regarding age and diagnostic 
characteristics of the sample. Studies pairing OT with a therapeutic activity or social training 
are highly needed, although design and outcome measures across studies will need to be 
similar in order to better interpret and compare results in ASD participants.
Investigating adults with ASD, Anagnostou et al. (2012) studied the safety and therapeutic 
effects of IN-OT with respect to two core symptom domains: social cognition and 
functioning, and RRB. They performed a randomized, double-blind, placebo-controlled 
parallel trial of IN-OT versus placebo. This was the first study to employ a treatment trial of 
daily administration of IN-OT in ASD. Overall, the IN-OT was well tolerated when given 
daily and no serious adverse effects were reported. This pilot study suggested therapeutic 
potential with daily administration of IN-OT in this population of adults with ASD. This six-
week study noted improvements in social cognition, quality of life, RRB, and some 
measures of emotional well-being with IN-OT, in essence, improvement in the core domains 
of ASD. It may be important to note that reports of individual differences in the response to 
IN-OT are increasingly observed, although sample sizes in studies will need to be larger to 
explore individual response variation.
2.2. OT/AVP plasma levels in ASD
The inability to directly access the brain’s oxytocinergic pathways has constrained human 
research. Therefore, peripheral OT levels have been used as proxies for OT levels in the 
brain. A widely used measurement is plasma OT, although urine and salivary OT levels 
have also been explored in some studies. A range of studies have observed associations 
between peripheral OT/AVP levels and social stimuli (Kenkel et al., 2012; Schneiderman et 
al., 2012; Schradin et al., 2013; Seltzer et al., 2010; Wismer Fries et al., 2005; Zhong et al., 
2012).
As early as 1996, it was suggested by a number of researchers, including Waterhouse et al. 
that dysfunction in the OT and AVP systems might contribute to the atypical social 
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behaviors in ASD. Two years later by studying the OT plasma levels from 29 ASD and 30 
age-matched typical control children, Modahl et al. (1998) reported low levels of plasma OT 
in the children with ASD. In another study, which utilized Wing’s topology, children were 
classified as “aloof”, “active but odd” and “overly formal” (Leekam et al., 1997). The lowest 
OT levels were found in the “aloof” subgroup. This suggested that the most severe socially-
aloof symptoms were associated with more OT dysfunction.
Building on these results with the same study sample, Green et al. (2001) conducted another 
OT study and examined the forms of the OT peptide found in affected and unaffected 
children. Their results showed that there was an increase in OT-X, the precursor for OT, as 
well as an increase in the ratio of OT-X/OT associated with the reduction in OT observed in 
the patients with ASD. During the normal production of OT, the extended form (OT-X) is 
cleaved by enzymatic activity to yield the active peptide OT. There was also a positive 
correlation between OT-X and checklist items associated with ASD including stereotypies; 
OT-X correlated negatively with an item describing abnormalities in comfort giving within 
the ASD group. Consequently, changes in OT processing, specifically a failure to 
completely process the prohormone OT-X, might lead to a deficiency in OT, thus 
exacerbating some of the symptoms of ASD, such as features of social deficits. To our 
knowledge this study has not been replicated. Furthermore, other studies often in older 
patients have failed to report an OT deficiency (Jansen et al., 2006; Miller et al., 2013). 
Future studies may benefit from the measurement of OT-X in addition to plasma OT given 
the diverse methods employed for assaying OT, and the finding that the failure to process 
this prohormone can lead to a deficiency of OT.
Recently, connections between peripheral OT/AVP levels and ASD were investigated 
(Miller et al., 2013). Miller et al. measured OT and AVP plasma levels in 75 boys and girls 
(40 high-functioning ASD, 35 typically developing) aged 8–18 years. Miller et al. not only 
reported associations between the plasma levels and ASD behaviors, but sex differences as 
well. Higher levels of OT were observed in all girls, and all boys had significantly higher 
levels of AVP. The higher OT levels were associated with greater anxiety in all girls, and 
with better pragmatic language in all subjects. Gender differences were also noted within the 
ASD sample. A positive association between AVP levels and RRB was reported in ASD 
girls, although a non-significant association with RRB was found in boys with ASD. 
Because of the limited number of girls affected by ASD, few other studies have sampled a 
large enough sample size of girls to investigate gender differences in OT plasma levels or 
response to exogenous administration.
Some studies have examined OT levels in addition to other hormones and blood biomarkers. 
In a study of adults with ASD, basal OT levels and heart rate were elevated in the ASD 
group compared to healthy controls. These adults with ASD showed normal cortisol 
responses to a public speaking task, but no change in norepinephrine, epinephrine, OT or 
AVP (Jansen et al., 2006). Recently, Hammock et al. (2012) analyzed correlations between 
the biomarkers of plasma OT and whole-blood serotonin (5-HT) levels in children and 
adolescents diagnosed with ASD and not on medications. Animal studies have shown that 
OT and 5-HT influence each other’s release (Bagdy and Kalogeras, 1993; Jorgensen et al., 
2003; Yoshida et al., 2009) and there have been many reports of hyperserotonemia within a 
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subgroup of individuals with ASD (Abramson et al., 1989; Chugani et al., 1999; Kuperman 
et al., 1985; Leboyer et al., 1999; Leventhal et al., 1990; Schain and Freedman, 1961). OT 
and 5-HT were negatively correlated with each other in the Hammock et al. (2012) study. 
Whole blood 5-HT was found to be negatively correlated with age, having lower levels in 
adolescence than in childhood. This OT/5-HT relationship was especially prominent in 
children younger than 11 years old. Age may be an important covariate, because some 
studies do not find OT deficiencies or have reported higher than expected OT levels in their 
ASD samples (Jansen et al., 2006; Miller et al., 2013). OT like 5-HT may change after 
puberty according to recent data (Hammock et al., 2012).
Interest in parental bonding has led to the study of OT levels in parents of typical children, 
and more recently parents of children with ASD. An association between peripheral OT and 
parental care, both maternal and paternal, was reported by Feldman et al. (2012). When 
comparing parents and non-parents, parents were found to have higher levels of OT. Higher 
plasma OT levels were also associated with longer durations of gaze synchrony and 
reporting of greater parental care during the parent’s childhood, while lower plasma OT 
corresponded to less parental touch. Subsequently, Xu et al. (2013) published a study 
comparing the OT and AVP plasma levels of mothers with and without ASD children in a 
Han population. They found that the mothers of ASD children had significantly lower 
plasma OT/AVP compared to the control mothers, as well as, a significant correlation 
between the plasma levels of the neuropeptides and the child’s autistic behavior scores.
Over the last few years studies measuring peripheral OT have increased. As discussed in 
McCullough et al. (2013) and Szeto et al. (2011), the methodologies can lead to vastly 
different results (increased values, decreased values or values differing by an order of 
magnitude). For example, Modahl et al. (1998) performed plasma extractions and then 
radio-immunoassays (RIA) whereas Miller et al. (2013) utilized an enzyme immunoassay 
(EIA) with different plasma preparation methods. Additionally, there is also specific lab 
generated RIA versus commercial EIA and RIA kits. When manufacturer instructions are 
followed, values obtained have a similar order of magnitude, but it has been noted that some 
of these kits may also be detecting closely related metabolites. Note that studies often 
prepared samples differently with varying plasma processing/extraction methods and use of 
different assay techniques. Future research will need to determine if differences observed in 
the resultant OT levels of ASD studies reflect differences in the study populations (i.e. age) 
and/or the methods for assaying OT. ASD is a very heterogeneous disorder and OT level 
differences may be specific to clinical and etiological subgroups within the broader ASD 
population. In addition, there is variability of OT plasma levels across typical and healthy 
populations. The inherent U-shaped distribution (Zhong et al., 2012) observed in normative 
populations may also add to variability seen in OT measurements in ASD studies.
2.3. OT and AVP animal and genetic studies in ASD
The search for genes and biological risk factors contributing to ASD and its core symptoms 
has resulted in a range of human and animal model studies. Recently, several researchers 
have examined how the OT system is altered in various animal model or influences social 
and repetitive behaviors. For example, the BTBR T+tf/J (BTBR) mice have low social 
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interactions, decreased vocalization in social settings and increased levels of repetitive self-
grooming, behavioral phenotypes similar to the core symptoms of ASD. Comparing BTBR 
to the standard inbred highly sociable mouse, C57BL/6J (B6), Silverman et al. (2010) found 
elevated OT in the PVN, plasma corticosterone (in the trunk), and glucocorticoid receptor 
(GR) mRNA in CA of the hippocampus in the BTBR. Measurements of the other 
neurochemicals (CRF in PVN, GR mRNA in CA2 and PVN) showed no differences 
between the strains.
Another model, the BALB/cJ, has low sociability across development (Brodkin, 2007). A 
substrain of the BALB/cJ, the BALB/cByJ mouse, was also characterized as a good ASD 
model (Brodkin, 2007; Moy et al., 2007). These mice displayed low sociability with intact 
olfaction, locomotor activity and relatively high levels of anxiety. Similarly, the C58/J 
mouse is another ASD mouse model described in 2010 by Ryan et al. (2010). These mice 
show low sociability and deficits in social communication. Most striking, however, is their 
abnormal RRB including increased rates of pivoting, back flipping, upright scrabbling and 
“jack-hammer” jumping. All the traits are found in both the males and females of the C58/J 
strain. Recently, the reactions of the BALB/cByJ and C58/J strains to OT administration 
were compared (Teng et al., 2013).
Teng et al. (2013) did not only note the different reactions to OT administration between 
BALB/cByJ and C58/J, they also studied whether acute versus subchronic administration 
had differing outcomes (see paper for drug and experimental timeline). Both strains were 
administered OT peripherally via intraperitoneal administration. Acute administration in 
BALB/cByJ showed no change in sociability, and RRB were not assessed in this timeline. 
However, in the subchronic regimen BALB/cByJ mice displayed a significant increase in 
social behaviors. Subchronic OT administration in the C58/J model also induced prosocial 
effects. In male mice these effects appeared two weeks post treatment, but the prosocial 
effects were evident in female mice sooner. Regarding RRB, Teng et al. observed a decrease 
in repetitive behaviors with increased self-grooming after an acute single dose of OT, in the 
C58/J mice. Most notably these studies have provided insight into how the genetic 
heterogeneity observed in humans may account for the wide variety and degree of behaviors 
seen in ASD. Additionally, the Teng et al. study highlighted how treatments can be 
dependent on both genotype and dose regimen. It is striking that all three mouse models of 
ASD have alterations in the OT system or respond to OT administration. This suggests that 
OT may be affected downstream in strains of mice that have different etiological factors 
influencing social and repetitive behaviors.
As the animal models have shown, the genetic heterogeneity of individuals with ASD could 
also account for the complexity of the disorder’s genetic etiology. In a recent review 
(Ebstein et al., 2009), genetic polymorphisms of receptor and pathway regulators of OT and 
AVP, such as AVPR1a, OXTR, neurophysin I and II, and CD38 were discussed. In this 
review, Ebstein and colleagues presented preliminary data regarding their findings about 
CD38, a transmembrane glycoprotein involved in OT secretion and associated with OT 
plasma levels. The group genotyped 12 tag single nucleotide polymorphisms (SNPs) across 
CD38 in 170 ASD trios. IQ and social skills via Vineland Adaptive Behavior Scales 
(VABS) were assessed in the sample. They found a significant association between CD38 
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SNPs and categorical ASD measures, assessed by the Autism Diagnostic Interview - 
Revised (ADI-R; Lord et al., 1994) and Autism Diagnostic Observation Schedule - Generic 
(ADOS-G; Lord et al., 2000). Significance was also observed between VABS scores and 
four CD38 SNPs, haplotypes and VABS, and CD38 mRNA levels and VABS. Two studies 
in 2010 further supported a role for CD38 in ASD. Lerer and colleagues (2010) noted a 
reduced expression of CD38 in the lymphoblastoid cells of patients with ASD as compared 
to “unaffected” parents. Then Munesue et al. (2010), observed a CD38 SNP in association 
with high functioning ASD in some populations. In 2012, several CD38 studies were 
completed that looked at the association of CD38 and ASD. In particular, Sauer et al. (2012) 
researched the common CD38 variant, rs3796863, in healthy young men. This SNP stood 
out in the ASD association studies performed by Lerer et al. (2010) and Munesue et al. 
(2010). Data were attained in a double-blind placebo-controlled crossover design using IN-
OT. The subjects performed two tasks following administration of OT or placebo: (1) a face 
matching task, and (2) a gaze processing task. They found that the men with the ASD risk 
allele had significantly slower reaction times (RT) during the face matching task and that it 
was specific to social versus non-social stimuli. IN-OT reduced RT in the risk group. Gaze 
processing did not yield any significant results. Functional MRI data also were attained as 
the subjects performed the tasks. Sauer et al. (2012) hypothesized decreased activity in the 
amygdala and fusiform brain regions of the risk allele group given the results of previous 
studies (Jemel et al., 2006; Schultz, 2005). Unexpectedly, they saw increased activation in 
the fusiform brain regions. This led them to conclude that while more research needs to be 
done to confirm their findings, the link between CD38, the processing of social information 
and ASD was further solidified.
Other researchers have looked directly at the OXTR gene, to find possible genetic links 
between OT and ASD. Wu et al. (2005) genotyped four SNPs across OXTR in 195 Chinese 
Han ASD trios. With Family Based Association Testing (FBAT), they revealed significant 
associations between ASD and two OXTR SNPs (rs2254298, rs53576). When the markers 
were combined to create haplotypes, significant associations were found for all markers and 
especially in haplotypes containing rs53576. Following up the Wu et al. study, Jacob et al. 
(2007) researched rs53576 and rs2254298 in a Caucasian sample with strictly defined 
autism. They genotyped the OXTR SNPs in 57 autism trios. In this sample a significant 
association was observed between diagnosis and rs2254298. While the G allele was more 
frequent than the A allele, of note was the overtransmission of the G allele to the autistic 
Caucasian probands versus over-transmission of the A allele in the Chinese Han sample. 
Additional studies by Yrigollen et al. (2008) and Campbell et al. (2011) continued to build 
an association between the OT system and ASD. Yrigollen and colleagues hypothesized that 
genes associated with affiliative, social, and/or bonding behaviors would also be associated 
with ASD and several of its symptoms. Therefore, they studied 177 ASD probands from 151 
families and they found the statistical strength was in the OXTR results. Different OXTR 
SNPs were significantly associated with stereotyped behaviors, communication skills, the 
multivariate ADI phenotype and multi-measurement variable overall diagnosis. Also, there 
was a significant SNP in the OXT/AVP region associated with stereotyped behaviors. In 
2011, Campbell and colleagues, utilizing a repository sample of 2333 individuals with ASD 
in 1238 pedigrees, analyzed 25 markers across OXTR and detected associations. Although 
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these SNPs had previously been associated with ASD diagnosis in studies, they also looked 
at associations with subphenotype measurements of social impairments in ASD and found 
associations with their selected three SNPs and ADOS, ADI-R and SRS measurement. 
While the results of the studies indicate a need for further research, these genetic studies 
have laid the foundation linking OT, social tasks, and more broadly ASD.
3. Prader–Willi syndrome and OT
Prader–Willi syndrome (PWS) is a complex disorder with multisystem effects and a distinct 
behavioral phenotype. It occurs in approximately 1/10,000–1/30,000 births, and is initially 
characterized by severe infantile hypotonia and difficulty feeding, although later in infancy 
and into adolescence individuals with PWS often eat excessively and develop morbid 
obesity. Other characteristics of PWS include hypo-gonadism, short stature, small hands and 
feet and strabismus. The cognitive phenotype is marked by delayed motor and language 
development, and behavioral difficulties including compulsive behavior, stubbornness and 
temper tantrums (Bittel et al., 2007b; Cassidy et al., 2011). The many behavioral and 
psychiatric manifestations of PWS are evident in early childhood, and are characterized by 
hyperactivity, impulsivity, temper tantrums, emotional lability, anxiety and repetitive 
behavior (Borghgraef et al., 1990; Gross-Tsur et al., 2001; Whitman and Accardo, 1987). 
Often this phenotype is suggestive of ASD as well as attention deficit hyperactivity disorder 
(ADHD; Cassidy et al., 2012). Face processing is also altered in individuals with PWS, as 
they have difficulty reading facial expressions (Whittington and Holland, 2011).
The cause of PWS is the lack of expression of specific paternal genes located on 
chromosome 15q11.2-q13. Many of the genes expressed in this region come from the father, 
as those from the mother are normally inactivated. Consequently, either a lack of expression 
or absence of the paternal copy of the genes in this region leads to no expression (Saitoh et 
al., 1997). This may occur through microdeletions in the paternal chromosome, no copy of 
the paternal chromosome paired with two copies of the maternal chromosome—uni-parental 
disomy (UPD), or imprinting defects due to epige-netic causes (Cassidy et al., 2012). The 
genes expressed in this region have been studied at length to develop models of PWS and to 
delineate their roles in the different aspects of the PWS phenotype. Such studies are 
complicated by differences in the behavioral phenotype between individuals with deletions 
and those with UPD, as those with UPD have a less severe phenotype (Bittel et al., 2007a) 
and higher verbal IQ scores (Dimitropoulos et al., 2000).
While the deletion of no one individual gene has been found to cause PWS, research has 
shown that the lack of expression of multiple genes may be central to the syndrome’s 
expression. Specifically, five polypeptide coding genes, namely MKRN3, MAGEL2, 
MAGED1, NECDIN and SNURF-SNRPRN, have been shown to be centrally involved in 
PWS. Animal models lacking one of these genes have been developed for Magel2 
(Boccaccio et al., 1999), Maged1 (Dombret et al., 2012), Necdin (Lavi-Itzkovitz et al., 2012; 
Muscatelli et al., 2000) and Snurf (Tsai et al., 1999), although none of these individual gene 
disruption models completely recapitulates the PWS phenotype.
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Another line of approach to elucidate the physiological underpinnings of PWS has been to 
examine the OT system in individuals with PWS as well as in animal models. There is a 
deficit of OT producing neurons in the PVN of persons with PWS (Swaab et al., 1995), as 
well as lower levels of OT in CSF (Martin et al., 1998). IN-OT administration increases trust 
in others and decreases disruptive behavior in individuals with PWS (Tauber et al., 2011). In 
addition, administration of OT has also been shown to rescue behavior in a Maged1 deletion 
model of PWS in which there is a decrease in hypothalamic OT (Dombret et al., 2012). 
Although rescue was not attempted in the Necdin model, this mutant also shows a reduction 
in OT-producing neurons in the hypothalamus (Muscatelli et al., 2000). Consequently, there 
appears to be disruption of the OT system in individuals with PWS, which is recapitulated in 
different animal models. However, the exact mechanism of OT dysregulation is unclear.
4. Williams syndrome and OT
Williams syndrome (WS) was first described over 50 years ago (Williams et al., 1961). The 
first reported cases were focused on infants with hypercalcemia, developmental delays, 
cardiac malformations and dysmorphic facial features (Morris, 1993). However, better 
characterization of this syndrome has elucidated a distinct behavioral phenotype marked by 
an increased social drive paired with social fearlessness, poor judgment, difficulty forming 
peer relationships and high anxiety levels (Jarvinen et al., 2013). The cause of this disorder 
has been determined to be a deletion of 25–30 genes in the q11.23 region of either maternal 
or paternal chromosome 7 that spans approximately 1.5 megabases (Ewart et al., 1993; 
Korenberg et al., 2000; Lowery et al., 1995; Schubert, 2009). ELN, the gene for elastin, was 
the first deleted gene identified and its absence is indicative of a diagnosis of WS. While 
ELN disruption affects connective tissue, particularly of the aorta (Lowery et al., 1995), 
other genes such as LIMK1, CYLN2, GTF2I and GTF2IRD1 are involved in the behavioral 
phenotype of WS (Jarvinen-Pasley et al., 2008). The deletion of Gtf2i as well as Gtf2ird1 
has been shown to be involved in the social pheno-type specifically (Proulx et al., 2010; 
Sakurai et al., 2011).
The social phenotype associated with WS is striking due to the hypersociability of the 
affected individuals, as well as the preference for novel social over non-social stimuli 
(Jarvinen-Pasley et al., 2008; Jarvinen-Pasley et al., 2010) and increased eye contact (Mervis 
et al., 2003). In addition, the speech of individuals with WS is marked by high levels of 
socially engaging language as compared to controls or individuals with other developmental 
disorders such as Down Syndrome (Jarvinen-Pasley et al., 2010; Jarvinen et al., 2013). 
However, this does not translate into the development of social relationships as individuals 
show difficulty with social adjustment (Gosch and Pankau, 1994, 1997) and social judgment 
(Einfeld et al., 1997; Gosch and Pankau, 1997). In addition, affected individuals show 
deficits in social understanding, as evidenced by difficulty identifying affect (Gagliardi et 
al., 2003; Plesa-Skwerer et al., 2006) or other’s mental states (Jarvinen-Pasley et al., 2008).
The high sociability of individuals with WS positions this syndrome as a good mechanism 
through which to understand the biological underpinnings of social behavior. Mouse models 
of WS include GTF2I deficient mice which display increased social interaction with novel 
mice and diminished social habituation (Sakurai et al., 2011) and Gtf2ird1 deletions, which 
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also show increased sociability (Proulx et al., 2010). Recently, de novo duplications of 
regions of 7q11.23 have been shown to be associated with ASD, whereas deletions of the 
same region lead to WS (Sanders et al., 2011). Such opposite effects of gene expression 
leading to markedly contrasting phenotypes raises the issue of dosage effects, but it should 
be noted that both ASD and WS phenotypes include abnormal social relationships, although 
through different mechanisms. Whereas individuals with WS show prolonged face gaze, 
those with ASD display reduced face gaze (Riby and Hancock, 2009). In addition, although 
children with WS and ASD display high levels of anxiety, individuals with ASD have higher 
levels of RRB as well as greater rates of social phobia and separation anxiety (Cascio et al., 
2012).
As deletions or increased expression of genes in the region defining WS can lead to the 
contrasting phenotypes of WS or ASD, respectively, the possibility of dysregulation of OT 
was examined by Dai et al. (2012). They show increased baseline levels of OT in individuals 
with WS as compared to controls. Additionally, OT levels correlated positively with 
increased approach to strangers as well as decreased adaptive social behaviors. These results 
suggest that there may be a dose dependent effect of OT, as high levels may impair adaptive 
social behavior and may partly underlie the maladaptive social phenotype of WS.
5. Fragile X syndrome
Named for the fragile site observed at Xq27.3, Fragile X Syndrome (FXS) is the most 
common inherited form of intellectual disability and the most common known single gene 
mutation associated with ASD (O’Donnell and Warren, 2002). Prevalence estimates range 
from ~1 case in 1000 to 1 case in 4000 males and has settled at 1 case in 6000 worldwide for 
females (Brown, 1990; Morton et al., 1997; Turner et al., 1996; Webb, 2010). This rare 
genetic disorder is characterized by specific physical features, as well as cognitive and 
behavioral phenotypes (Berry-Kravis et al., 2002, 2011; McLennan et al., 2011). The 
physical features can include: a long narrow face with large protruding ears, connective 
tissue abnormalities (i.e. hyperextensive joints), macroorchidism, macrocephaly, obesity 
(especially in young males), loose skin over the hands, a high arched palate, a vertical 
plantar crease and flat feet (Moy et al., 2009; Schapiro et al., 1995). The behavioral and 
social characteristics of FXS include: hyperactivity, attention difficulties, mood lability, 
compulsive and perseverative behaviors, some aggressive outbursts, learning deficits, 
developmental delays (including delayed speech development), social shyness and gaze 
avoidance, sensory hypersensitivity and withdrawal from touch, stereotypic movements and 
behaviors (i.e. hand flapping and rocking), poor motor coordination and echolalia 
(Hagerman et al., 2009; Hall, 2009; Hall et al., 2009; Moy et al., 2009). Many of these 
behaviors are linked to the anxiety level of the individual, a meaningful link because 
physiological studies have noted increased sympathetic and decreased parasympathetic 
activity and poor coordination between the systems in children and adolescents with FXS 
(Hall et al., 2009).
Cognitive tests have indicated a specific pattern of strengths and weaknesses. FXS 
individuals exhibit deficits in visuospatial tasks, quantitative skills, short-term and working 
memory, expressive language skills, sequential processing and executive function (Berry-
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Kravis et al., 2002; Cornish et al., 1999; Freund and Reiss, 1991; Hall et al., 2012; Kwon et 
al., 2001; Maes et al., 1994). Relative strengths include receptive language skills, visual 
memory, acquisition of factual information, imitation skills and gestalt processing (Berry-
Kravis et al., 2002). This population also has susceptibility to certain other neuropsychiatric 
disabilities including ASD, ADHD, anxiety disorders, and neurological disorders such as 
epilepsy (Hessl et al., 2001; Pretorius et al., 1998). While the genetic cause of FXS has been 
found, the neurological basis of FXS symptoms continues to be unknown. MRI studies have 
found that individuals with FXS have enlarged lateral ventricles and increased caudate 
nucleus volumes relative to control subjects (Reiss et al., 1995). Anatomical studies of post-
mortem brains have revealed that dendritic spines of neocortical pyramidal neurons of FXS 
subjects are longer and thinner than those of matched controls, indicating perhaps the spines 
fail to mature normally in FXS patients (Hinton et al., 1991; Irwin et al., 2001; Rudelli et al., 
1985; Wisniewski et al., 1991).
The majority of FXS patients have social anxiety and almost a third have symptoms that 
overlap with ASD (Hagerman et al., 2010). Published studies have reported the prevalence 
rate of FXS and autistic behaviors/ASD diagnosis to range from 25–47%, however sample 
sizes are often small (Hatton et al., 2006; Morton et al., 1997). Like FXS and ASD, autistic 
symptoms are more common in males than females. Individuals with both FXS and ASD 
often have poorer developmental outcomes, lower cognitive abilities, lower levels of 
adaptive behavior and more problem behaviors than FXS individuals with fewer autistic 
behaviors. Of the individuals with FXS and autistic behaviors, 15–40% of males and a few 
females meet the diagnostic criteria for ASD (Berry-Kravis et al., 2002). This group also 
tends to present with more severe communication deficits, stereotyped behaviors, and social 
anxiety versus social disinterest. Additionally, males present with more severe 
developmental delays than females. Overlapping behaviors between ASD and FXS, such as 
eye gaze avoidance (Hall et al., 2009), have led many scientists to study FXS as a way to 
understand and possibly target treatment for ASD. Some of the medical problems exhibited 
within this population include seizures (15–20% of male children, usually limited to 
childhood), gastroesophageal reflux, failure to thrive in early infancy, hypotonia, recurrent 
otitis media and sinusitis, vision problems, cardiac valve prolapse, sleep disorders, and 
orthopedic issues and dental malocclusions. In the few girls studied with FXS, these medical 
problems are more variable (Berry-Kravis et al., 2002).
Diagnosis is based on DNA analysis that identifies the number of CGG repeats in the fragile 
X mental retardation 1 (FMR1) gene at the Xq27.3 site (Turner et al., 1996). In most 
affected individuals, this genetic disorder is caused by a trinucleotide (CGG) repeat 
expansion in the 5’ untranslated (promoter) region of the FMR1 gene. FMR1 encodes the 
fragile X mental retardation protein (FMRP); a 69kDa protein found in most adult and fetal 
tissues, high concentrations are noted in the brain and testes. The expression of FMRP in the 
brain seems to be experience dependent and is produced in the soma and near the synapse 
(Berry-Kravis et al., 2002, 2011). FMRP is essential to the shaping of dendritic spines 
(Davidovic et al., 2011). The protein and network of mRNA targets and interacting proteins 
contribute to several forms of synaptic plasticity involving learning and memory processes, 
notably induced by activation of type I metabotropic gluta-mate receptor (mGluR; 
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Davidovic et al., 2011). Mice lacking FMRP have impaired long-term potentiations in 
somatosen-sory cortex (Li et al., 2002), visual cortex (Wilson and Cox, 2007), olfactory 
cortex (Larson et al., 2005), cingulate cortex, and amygdala (Zhao et al., 2005) and 
enhanced long-term depression in hippocampus (Huber et al., 2002). In synapto-somal 
preparations, stimulation of mGluR results in a FMRP-dependent increase in protein 
synthesis (Weiler et al., 1997, 2004). It is hypothesized that a decrease in Fmr1 functionally 
affects the protein interaction network with direct consequences on signaling cascade and 
cellular metabolism (Davidovic et al., 2011). There are two different FMR1 mutations, full 
mutation and permutation (Goodrich-Hunsaker et al., 2011a, 2011b). Premutation, 
associated with Fragile X-associated tremor/ataxia syndrome (FXTAS; Wang et al., 2010), 
has a repeat length of 50–200 and does not usually cause mental deficits, but shyness, 
anxiety, and premature ovarian failure have been known to occur. Premutations do appear 
however to influence translation of FMR1 mRNA (Feng et al., 1995). In many individuals 
with premutations, excess FMR1 mRNA is produced, yet below normal FMRP is 
synthesized (Tassone et al., 2000a, 2000b) and may contribute to approximately 10% of 
male and 2–3% of female ASD cases (Wang et al., 2010). Upon female transmission the 
premuta-tion can become a full mutation. FXS is caused by full mutation which is 4200 
trinucleotide repeats, and results in hypermethylation of the gene and transcriptional 
silencing (Tassone et al., 2000a). This creates an FMRP deficiency in the brain, which leads 
to FXS presentation (McLennan et al., 2011; Tassone et al., 2000a). Very rarely have other 
mutations in the FMR1 gene involving deletions (Gedeon et al., 1992; Wohrle et al., 1992) 
or a point mutation (De Boulle et al., 1993) resulted in symptoms identical or even more 
severe than FXS.
5.1. IN-OT as treatment for FXS
Evidence has supported the investigation of OT as a treatment for FXS (Bartz and 
Hollander, 2006; Hall et al., 2012; Hollander et al., 2007). As described earlier OT, released 
endogenously or given exogenously, has been associated with positive social behaviors, 
reductions in anxiety, obses-siveness and stress reactivity, the central release of AVP and 
other peptides such as corticotropin-releasing factor, and may serve to counter the defensive 
behavioral strategies associated with stressful experiences (Carter, 2007). However, similar 
to ASD, available treatments for FXS focus on managing symptoms: stimulants are 
prescribed for attention deficit and hyperactivity; SSRI and antipsychotics treat aggression 
associated with anxiety; and carbamazepine are used for treatment of seizures (Hampson et 
al., 2011). Currently, there are no treatments on the market targeting the molecular 
abnormalities of FXS (Gurkan and Hagerman, 2012). Recent studies have begun to 
investigate IN-OT due to the autistic-like behaviors observed in FXS, and the social and 
anxiolytic effects of OT.
As of the time of publication, very few studies had been performed to research the effect of 
IN-OT on FXS, especially in humans. One such study was conducted by Hall et al. (2012). 
They set up a randomized double-blind placebo-controlled single-dose trial performed with 
intranasal administration of placebo, 24IU OT and 48 IU OT. Studying eight low 
functioning males between the ages of 13 and 28 years with FXS, they hypothesized that the 
prosocial and anxiolytic effects of OT would reduce, if not alleviate, socially inappropriate 
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behaviors and social anxiety. The group collected eye gaze frequency, heart rate, respiratory 
sinus arrhythmia, heart rate variability (HRV) during two social challenges (10 min total in 
length), and salivary cortisol levels before and after the challenge, which was conducted 50 
min after OT administration.
Confirmation of the hypothesis that OT would have beneficial consequences in FXS would 
be an increase in eye gaze frequency, a reduction in physiological arousal, and a decrease in 
salivary cortisol. The researchers observed a significant main effect with OT. As compared 
to placebo, 24IU OT led to a significant increase in eye gaze frequency. They found a 
significant decrease in salivary cortisol for the 48 IU dose as compared to placebo. No 
effects were observed in the physiological measurements (HR, HRV, and RSA), however, 
given the small sample and heterogeneous population additional research is needed. Based 
upon the data to date, Hall and colleagues hypothesized that in FXS administration of OT 
may dampen amygdala reactivity towards social stimuli that causes anxiety (Kirsch et al., 
2005; Petrovic et al., 2008), decrease HPA axis activation, and increase social motivation 
(Witt and Insel, 1992; Witt et al., 1992).
5.2. Animal models: a way to look at moderators of neurodevelopmental pathways and 
outcomes?
Animal models have proven indispensable in the understanding of diseases and disorders, 
and in the development of pharmaceuticals used to treat them. The quality of an animal 
model is ascertained based on how well it can meet certain criteria of validity. Three of these 
criteria are construct, face and predictive validity (Bernardet and Crusio, 2006). How well 
the model’s behavioral traits resemble the core traits of the disorder is face validity. 
Predictive validity is established when a drug reduces or improves symptoms in both the 
model and human. Construct validity is the “quality” of the model, its ability to accurately 
measure or represent what it claims to be measuring (Cronbach and Meehl, 1955). There are 
several FXS animal models, three in mice and a drosophila model that meet multiple 
criteria.
Two homologous genes to Fmr1 in vertebrates are Fxr1 (fragile X related gene) and Fxr2. 
The genes are highly homologous at the protein structure level and bind mRNA and bind to 
FMRP. Their proteins, FXR1P and FXR2P are both expressed in the brain and specifically 
in cell bodies, but they are also found in the dendrites near the synapse. Both Fxr1 and Fxr2 
KO mice have been produced. FXR1P deficient (Fxr1−/−) mice die within 24 h of birth, 
while heterozygous mice exhibit abnormal limb musculature. Fxr2 KO have a normal 
lifespan, learning deficits similar to Fmr1 KO, and circadian rhythm deficits (Berry-Kravis 
et al., 2011). The fruit fly model, a mutant lacking dFmr1 (also known as dFxr) protein, 
exhibits overextension of neurites during development of mushroom bodies (brain region 
linked with memory) and have a behavioral phenotype that includes circadian rhythm 
abnormalities and altered courtship behavior (Berry-Kravis et al., 2011; Gatto and Broadie, 
2009).
One of the best characterized animal models of FXS was developed in 1994 by the Dutch-
Belgian Fragile X Consortium. This mouse model, which lacks FMRP throughout its 
lifespan, corresponds to the molecular endpoint of the human disease. This mouse was 
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created by inserting a neomycin cassette into exon 5 of the murine Fmr1 gene. The insert 
disrupts the transcription of Fmr1 mRNA causing an absence of FMRP. Even though the 
cause may not be identical, this mouse model exhibits behavioral similarities to FXS. Fmr1 
KO, in comparison to the wild-type (WT) strain, are described as having lower than normal 
levels of initial social interactions (Mineur et al., 2006), fail to show a preference for social 
novelty, and display inappropriate social responses (Pietropaolo et al., 2011). In contrast, the 
OT and AVP knockout (OTKO or AVPKO) mice display high levels of social contact that 
does not diminish over time, but also fail to show indication of familiarity (Crawley et al., 
2007).
While macroorchidism is observed in the Fmr1 KO animals (Bakker et al., 1994) as well as 
in FXS patients, the behavioral patterns differ between the patients and the KO. By most 
accounts Fmr1 KO mice appear to have relatively normal behavior, but research has shown 
that the behavioral and cognitive deficits of the KO are actually quite subtle and parallel 
FXS patients (Berry-Kravis et al., 2002; D’Hooge et al., 1997; Paradee et al., 1999; Peier et 
al., 2000). Among the behavioral phenotypes displayed in Fmr1 KO are deficits in object 
recognition memory (including a failure to habituate to objects), and impairment of spatial 
memory (Mineur et al., 2002).
Several studies indicate that Fmr1 KO mice are hyperactive and show indications of 
increased anxiety (Bakker et al., 1994; Mineur et al., 2002; Spencer et al., 2005) and sensory 
hyperre-sponsiveness, especially to auditory stimuli (Chen and Toth, 2001; Frankland et al., 
2004; Nielsen et al., 2002). Loud tones may induce audiogenic seizures. Fmr1 KO also 
exhibit abnormal social interactions, including a general reduction in social contact and a 
failure to show social recognition (Bernardet and Crusio, 2006; Mineur et al., 2006; Spencer 
et al., 2005; Yan et al., 2004). In some tasks there is variability in the results (i.e. complex 
visual and auditory discriminant tasks and activity level in an open field). The symptom 
variability among mouse models for FXS may be due to differences in genetic backgrounds. 
A similar hypothesis has been proposed to explain the variability observed in the symptoms 
of FXS patients. For example, in research by Pietropaolo et al. (2011), the validity of the 
Fmr1 KO mouse on the B6 background was tested against WT and Fmr1 KO on the FVB 
background. They found the Fmr1 KO on the B6 background to be a good model for FXS 
and a suitable model for ASD (Pietropaolo et al., 2011; Yan et al., 2004).
These mice also have neuropathologic phenotypes that are similar to FXS patients including 
density of dendritic spines of pyramidal neurons in the visual and somatosensory cortices 
that are greater in adult Fmr1 KO than WT. Some brain areas, in both mice Fmr1 KO mice 
and FXS patients, have spines that appear similar to developing versus mature spines 
(Berry-Kravis et al., 2002). Absence of FMRP in both humans and mice results in improper 
development of dendritic spines on cortical pyramidal neurons (Comery et al., 1997; Irwin et 
al., 2000; Irwin et al., 2001; Irwin et al., 2002). The use of the Fmr1 KO mouse has also 
provided some insight into the normal cellular function of FMRP. The subtle cognitive 
deficits of Fmr1 KO mice present difficulties for preclinical testing of potential treatments, 
and highlight how complex the relationship between the mouse and human phenotypes are. 
One possibility is that the cognitive processes in which FMRP plays a vital role in humans 
are poorly developed in mice; thus mice lacking FMRP are not particularly disabled, at least 
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compared to severely-affected patients. A second possibility is that other proteins can 
compensate for FMRP in the mouse but not in the human. Third, the behavioral paradigms 
thus far applied to the mouse model do not efficiently assay or correlate with the cognitive 
domains most affected in individuals with FXS.
5.3. Examining OT in neurodevelopmental animal models: a way to examine early effects?
Below we present preliminary data examining the OT and AVP systems in a mouse model 
in order to learn more about FXS pathway interactions during development. The methods 
used in this study are described in the text for Fig. 1. These preliminary results, based upon 
counts of immune-reactive cells, suggest a reduction in both OT-positive (Fig. 1) and AVP-
positive (Fig. 2) cells in the PVN of Fmr1 KO as compared to WT (Table 2). A trend, 
although not significant, towards lower OT-positive cells was also noted in the SON (Table 
3). To analyze possible differences in the OXTR, the abundance of OXTR-immunoreactive 
cells were also measured in the hippocampus, retrosplenial granular and piriform cortices. 
None of these areas showed a significant difference in OXTR-immunoreactive cell density 
as compared to WT mice (p>0.05). The PVN is an important component of the HPA axis, 
and reductions in OT-positive and AVP-positive cells of the PVN might be associated with 
deficits in the capacity to regulate emotional reactivity. Earlier work in voles has suggested 
that either OT or AVP may support a general tendency toward social contact (Cho et al., 
1999). Thus, the absence of either OT or AVP in the presence of the other did not produce 
an “asocial” animal. However, selective social preferences, such as those necessary for pair 
bond formation, appear to require stimulation of both OT and AVP receptors. The 
importance of both OT and AVP to selective behaviors also may be supported by the fact 
that mice “knocked-out” for either OT or the OXTR no longer exhibited selective social 
memory (Young and Flanagan-Cato, 2012).
Although the preliminary data shown here for Fmr1 KO mice need to be replicated in a 
larger sample and in other animal models, we include these findings as an example of 
possible approaches to examining the role of peptides including, OT and AVP, in 
molecularly characterized genetic syndromes. Work across these models also could provide 
additional insight regarding the role of OT and AVP in early development, especially in 
syndromes in which atypical trajectories in social development occur.
6. Conclusion and next steps
Each of the disorders described here (ASD, PWS, WS and FXS) is unique and each 
condition is characterized by atypical social behaviors, often with a tendency toward high 
levels of anxiety. Given the importance of OT and AVP to mammalian social behaviors and 
anxiety, the neuropeptides’ investigative value in these syndromes is not unexpected. This 
review summarized the possible role of OT in these NDD (Table 4) through experiments 
conducted by others and ourselves.
Each of these early developmental disorders displays alterations in the OT system. These 
changes may impact behavior and emotional regulation through a variety of molecular and 
neuroendocrine pathways. For example, our preliminary data suggests a decreased number 
of OT-positive and AVP-positive cells in the PVN of Fmr1 KO mice, a mouse model for 
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FXS. Individuals with PWS have shown lower levels of OT in CSF (Martin et al., 1998) and 
fewer OT producing cells in the PVN (Swaab et al., 1995). A subgroup of ASD affected 
children also appeared to have lower plasma OT levels (Modahl et al., 1998). In contrast 
WS, which is characterized by hypersociability, had a positive correlation between OT 
levels and increased stranger approach and decreased adaptive social behavior (Dai et al., 
2012).
At present, the largest concentration of studies on the role of dysregulated OT pathways has 
been conducted in ASD. However, as new data are emerging it is striking that other 
disorders with phenotypes marked by abnormal social behavior, as well as anxiety (in some 
cases manifested by RRB) also appear to have abnormalities found within the OT system. 
For example, as in ASD, individuals with PWS have difficulty with social competence 
(Dimitropoulos et al., 2013), are aloof and avoid eye contact (Dimitropoulos et al., 2009). 
Furthermore, RRB is also evidenced in PWS (Greaves et al., 2006), although to a lesser 
degree than in ASD as measured by the Repetitive Behavior Scale-Revised (RBS-R; Flores 
et al., 2011). A subset of the genetic region associated with PWS is also associated with an 
increased risk for ASD, as maternally inherited duplications of the 15q11–13 region are 
associated with 1–3% of ASD cases (Bolton et al., 2001; Cook et al., 1997; Vorstman et al., 
2006).
WS and ASD also share commonalities as both are marked by abnormal social phenotypes 
and anxiety. However, unlike PWS, individuals with WS show a phenotype that is markedly 
different from ASD. Although both groups are at risk for anxiety, individuals with ASD 
show higher levels of social phobia and separation anxiety, as well as higher rates of RRB. 
However, individuals with WS have higher scores on measures of generalized anxiety 
(Rodgers et al., 2012). WS is characterized by an increase in OT levels (Dai et al., 2012), as 
well as a deletion of the 7q11.23 region, as opposed to a de novo duplication which leads to 
ASD (Sanders et al., 2011). It is likely that features of ASD and WS are manifestations of 
gene dosage effects on similar behaviors. Studies of FXS and ASD mechanisms may also 
inform each other, as mutations in mGluR5 can contribute to the diagnosis of FXS or ASD, 
and mGluR5 antagonists have shown promise in alleviating ASD symptoms in mouse 
models (Silverman et al., 2012) as well as FXS pathology. Due to the rarity of these 
disorders and the complex animal models needed to study them, many of these experiments 
have small sample sizes. However, these studies remain significant and together provide a 
motivation and direction for future research in NDD, especially disorders with dysfunctional 
social behaviors as a symptom.
As summarized in this review, the dysregulation of the OT system in animals and humans is 
associated with marked deficits in social behavior as well as anxiety. This commonality 
across multiple NDD may indicate a shared OT pathway that is affected during 
development. The use of animal models, particularly those developed for FXS, WS and 
PWS will provide insight into such a pathway, as these disorders have well characterized 
genetics. In contrast, there are over a 103 disease genes and 44 genomic loci reported to be 
involved in ASD (Betancur, 2011). However, unlike ASD research, there is a lack of human 
data on the pathophysiology of FXS, WS and PWS, and pharmacological interventions. 
Ideally, scientists want to identify specific molecular pathways to target distinct syndromes 
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and disorders for treatment. However, many effective medical treatments, such as drugs for 
hypertension, modulate common neurochemical or hormone pathways that are downstream 
from etiologically contributing factors. Combining the strengths of human and animal model 
studies across these NDD may provide important clues into the developmental role of OT. 
Additionally, as general mechanisms underlying social and emotional behaviors are 
specified, it may become possible to elucidate the complex neurophysiology of and create 
treatment targets for FXS, PWS, WS and ASD.
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Expression of OT in the paraventricular nucleus (PVN), as measured by ICC, is reduced in 
Fmr1 KO mice as compared to the wild-type (WT). Methods: The animal model was 
generated with WT and Fmr1 KO mice from a colony founded with stock obtained from the 
Jackson Laboratory (Bar Harbor, ME, USA) that was backcrossed onto a B6 background > 
10 generations. Mice were genotyped using primers described previously (the Dutch-
Belgian Fragile-X Consortium, 1994). Cells were stained using the immunocytochemical 
(ICC) staining procedures, following protocols described in early work on OT and AVP in 
voles (Yamamoto et al., 2004). All sections were double-stained for NeuN (a marker that 
stains cell nuclei only in neurons), which allowed precise localization of cytoarchitectonic 
boundaries. Stained sections were mounted on subbed slides and examined with OT and 
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AVP antibodies (OT antibodies were generously provided by M. Morris and AVP antibodies 
were obtained from MP Biomedical #647171, formerly ICN; Solon, OH, USA). Slices of 
tissue for each animal were categorized as described in (Paxinos and Franklin, 2004) and 
carefully matched across subjects to allow comparable sections. Imaged slides were 
captured at 10 ×, then coded and scored by an experimentally blind scorer using Image J 
(NIH, Bethesda, MD) software. OT and AVP stained cells in the PVN of the hypothalamus 
regions were stained separately for OT and AVP (N=6–7 mice per group). Boxed sampling 
areas were: 125 × 125 µm2 (PVN total staining density), 250 × 375 µm2 (PVN fibers), 93.75 
× 93.75 µm2 for cell counts bilaterally in both the PVN and SON.
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Expression of AVP in the paraventricular nucleus (PVN). In Fmr1 KO mice, as compared to 
the wild-type (WT) AVP expression is reduced as measured by ICC.
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Table 4
A Summary of OT Affects on NDD.
Disorder Neuropeptide system affected References
Autism spectrum Atypical (↓↑ observed) levels of OT in blood (human) Modahl et al. (1998)
disorders IN-OT ↑ social task performance and ↓ repetitive behaviors
(human)
Andari et al. (2010) and Hollander et al. (2003)
To be studied: human neuropathology and animal models For a more extensive list of human trials see Table 1
Prader–Willi syndrome ↓ OT producing cells in the PVN (human) Swaab et al. (1995)
↓ Level of OT in CSF (human) Martin et al. (1998)
IN-OT ↑ trust and ↓ disruptive behaviors (human) Tauber et al. (2011)
↓ Hypothalamic OT in Maged1 deletion model (animal) Dombret et al. (2012)
Williams syndrome ↑ OT levels (human) Dai et al. (2012)
To be studied: human neuropathology and animal models
Fragile X syndrome ↓ OT+ and AVP+ cells in the PVN (Fmr1 KO mice) See Tables 2 and 3, and Figs. 1 and 2
IN-OT ↑ eye gaze frequency (human) Hall et al. (2009) and Hall et al. (2012)
IN-OT ↓ salivary cortisol (human) Hall et al. (2012)
To be studied: human neuropathology
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